Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-06-19 Major Shareholding Noti…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "Major Shareholder Announcement" and details a change in ownership percentage by BlackRock, Inc., specifically noting when the ownership crossed the 5% threshold and subsequently fell below it. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2019-06-19 English
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
M&A Activity Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding a new licensing and collaboration agreement with Janssen Biotech for the development of a specific antibody product (HexaBody-CD38). This type of strategic partnership and licensing deal falls under M&A Activity (TAR) as it involves the development, commercialization, and potential future licensing of a pharmaceutical asset, which is a standard classification for corporate development and partnership announcements.
2019-06-11 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is titled 'Company Announcement' and details a significant business event: Genmab signing an exclusive worldwide license and option agreement with Janssen for a new antibody product (HexaBody®-CD38). It includes financial terms (option exercise fee, milestones, royalties) and strategic rationale. This type of announcement, detailing a major collaboration, financing aspect, or strategic partnership, fits best under 'Capital/Financing Update' (CAP) if it involves significant capital structure changes or fundraising, or potentially 'Regulatory Filings' (RNS) if it's a general market disclosure. However, since it explicitly details the financial structure of the deal (payments, royalties, development funding), it strongly aligns with updates on financing activities or major corporate transactions that impact capital structure, making 'CAP' a strong candidate. Given the options, and that it's a major corporate deal announcement rather than a standard earnings report or governance update, 'CAP' (Capital/Financing Update) is the most appropriate fit for a significant licensing/collaboration deal involving substantial future payments and development funding structure. It is not an ER, IR, 10-K, or a simple RPA/RNS announcement of a report, but the substance of the announcement itself.
2019-06-11 English
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a press release from Genmab A/S announcing that the U.S. FDA has granted Priority Review for a supplemental Biologics License Application (sBLA) for their drug, Daratumumab. This is a standard corporate regulatory announcement regarding drug development and FDA status. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a dividend or share transaction notice. Therefore, it falls under the general regulatory announcement category.
2019-05-30 English
Legal Proceedings Report 2019
Legal Proceedings Report Classification · 99% confidence The document is titled "Company Announcement" and details a specific regulatory event: the U.S. FDA granting Priority Review for a drug (daratumumab) and setting a PDUFA date. It includes key dates, scientific details about a clinical study (CASSIOPEIA), and company background. This format is characteristic of a press release announcing significant corporate or regulatory milestones, rather than a formal periodic report (like 10-K or IR) or a transcript. Since it is a direct announcement of a regulatory action and company news, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad announcement that doesn't fit the more specific categories like ER (Earnings Release) or CAP (Financing Update). Given the content is a direct announcement of a regulatory event, RNS is the most appropriate general classification.
2019-05-30 English
Regulatory Filings 2019
Regulatory Filings
2019-05-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.